<DOC>
	<DOC>NCT01298687</DOC>
	<brief_summary>The purpose of this study is to compare the incremental dosing of travoprost ophthalmic solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).</brief_summary>
	<brief_title>Divided Dose of TRAVATAN®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients with openangle glaucoma or ocular hypertension who meet the following IOP criteria: 1. Mean IOP ≥ 24 mmHg in at least 1 eye, with the same eye qualifying at 8 AM at both Day 0 and Day 1; 2. Mean IOP ≤ 36 mmHg in both eyes at all time points on Day 0 and Day 1. Must sign an informed consent form. Other protocoldefined inclusion criteria may apply. Females of childbearing potential who are pregnant, test positive on urine pregnancy test at the Screening Visit, intend to become pregnant during the study period, are breastfeeding, or are not using highly effective birth control measures. Current or history of ocular inflammation or infection in either eye within the past 3 months. Corneal thickness greater than 620 µm as determined by pachymetry in either eye. Severe visual field loss. Cup to disc ratio greater than 0.8 in either eye. Intraocular surgery within the past 6 months in either eye. Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>divided dose</keyword>
</DOC>